Login to Your Account

Pharma: Clinic Roundup

Friday, March 9, 2012
• Bristol-Myers Squibb Co., of New York, said research published in the New England Journal of Medicine showed that combining targeted radiation therapy with immunotherapy drug Yervoy (ipilimumab) fostered a strong immune response and a favorable clinical outcome in a patient with melanoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription